CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 161 enrolled
Drug / intervention
Alectinibdrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Documented diagnosis of NSCLC
  • ✓Age ≥18 years at initial NSCLC diagnosis
  • ✓Received alectinib treatment during study identification period
  • ✓At least 2 visits after index date during observation period
Key exclusion· 1
  • ✕Other primary cancer diagnosis within 5 years of index date (except non-melanotic skin cancer)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04351334
NCT04351334N/ACompleted
CompareCT.gov

Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With Alectinib

Pfizer·observational·Posted Apr 17, 2020·Updated Sep 19, 2024

In Brief

An observational study evaluating Alectinib for Non-Small-Cell Lung Carcinoma. Completed, enrolled 161 participants across 1 site.

Detailed Summary

This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 17, 2020
Enrollment StartMar 1, 2020
Primary CompletionNov 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.2 years ago

Interventions

Alectinibdrug

Observational treatment based on physician choice